Note 12 - Related Party Transactions	6 Months Ended
Jun. 30, 2022
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 12 -- RELATED PARTY TRANSACTIONS United Systems Milestone Scientific has a manufacturing agreement with United Systems (whose controlling shareholder, Tom Cheng, is a significant stockholder of Milestone Scientific), the principal manufacturers of its handpieces, pursuant to which it manufactures products under specific purchase orders, but without minimum purchase commitments. Purchases from this manufacturer were approximately $436,000 and $1.7 million, respectively for three and six months ended June 30, 2022. Purchases from this manufacturer were approximately $493,000 and $878,000, respectively for three and six months ended June 30, 2021. As of June 30, 2022 and December 31, 2021, Milestone Scientific owed this manufacturer approximately $720,000, and $548,000, respectively, which approximately $720,000 and $395,000 is included in accounts payable, related party, respectively, and $0 and approximately $153,000 is included in accrued expense, related party, respectively, on the unaudited condensed consolidated balance sheets. Milestone China See Note 6 of the notes to the unaudited condensed consolidated financial statements. Other In August 2016, K. Tucker Andersen, a significant stockholder of Milestone Scientific, entered into a three-year agreement with Milestone Scientific to provide financial and business strategic services. Expenses recognized on this agreement were $25,000 and $50,000 for three and six months ended June 30, 2022, and 2021. The Company engaged Mr. Trombetta as a consultant for a period of twelve months (beginning October 1, 2020, and ending September 30, 2021), to provide international business dental information and business contacts to the Company and provide consulting services for new international business and dental segments. For the three and six months ended June 30, 2021, the Company expensed $15,000 and $30,000, respectively, for services rendered by Mr. Trombetta. Mr. Trombetta received shares of the Company’s common stock. This agreement was terminated September 30, 2021, and therefore, no expenses were incurred for services rendered by Mr. Trombetta for the three and six months ended June 30, 2022. The Director of Clinical Affairs’ royalty fee was approximately $81,000 and $213,000 for three and six months ended June 30, 2022, respectively. The Director of Clinical Affairs’ royalty fee was approximately $111,000 and $248,000 for three and six months ended June 30, 2021, respectively. Additionally, Milestone Scientific expensed consulting fees to the Director of Clinical Affairs of $39,000 and $78,000 for three and six months ended June 30, 2022 and 2021, respectively. As of June 30, 2022 and December 31, 2021, Milestone Scientific owed the Director Clinical Affairs for royalties of approximately $81,000 and $123,000, respectively, which is included in accrued expense, related party, in the condensed consolidated balance sheet. On March 2, 2021, Milestone Scientific entered into a Royalty Sharing Agreement with Leonard Osser, the Company’s then Interim Chief Executive Officer, pursuant to which Mr. Osser sold, transferred and assigned to the Company all of his rights in and to a certain patent application as to which he is a co-inventor with Dr. Hochman, and the Company agreed to pay to Mr. Osser, beginning May 9, 2027, half of the royalty (2.5%) on net sales that would otherwise be payable to Dr. Hochman and his wife under their Technology Sale Agreement with the Company, the Hochman's having agreed with the Company pursuant to an addendum to such Technology Sale Agreement dated February 25, 2021 to reduce from 5% to 2.5% the payments due to them on May 9, 2027 and thereafter, with respect to dental products. Pursuant to a Succession Agreement dated April 6, 2021 between Mr. Osser and the Company: (i) the Employment Agreement dated as of July 10, 2017 between Mr. Osser and the Company, pursuant to which upon Mr. Osser stepping down as Interim Chief Executive Officer of the Company, the Company agreed to employ him as Managing Director, China Operations of the Company (the “China Operations Agreement”), and (ii) the Consulting Agreement dated as of July 10, 2017 (the “Consulting Agreement”) between the Company and U.S. Asian Consulting Group, LLC, a company of which Mr. Osser is a principal, the compensation under the China Operations Agreement was modified to reduce the overall compensation by $100,000 to $200,000, split equally between a cash amount and an amount in shares, and the compensation under the Consulting Agreement is increased by $100,000 to $200,000, equally split between a cash amount and an amount in shares, which shares were formerly payable under the China Operations Agreement. Compensation under the China Operations Agreement and the Consulting Agreement are payable for 9.5 years from May 19, 2021. The Company recorded expense of $50,000 and $100,000 related to the Managing Director, China Operations for three and six months ended June 30, 2022, respectively. The Company recorded expense of $50,000 and $100,000 related to the US Asian Consulting Group, LLC for three and six months ended June 30, 2022, respectively. The Company recorded expense of $25,000 related to the Managing Director, China Operations for three and six months ended June 30, 2021, respectively. The Company recorded expense of $25,000 related to the US Asian Consulting Group, LLC for three and six months ended June 30, 2021, respectively. As of June 30, 2022 and December 31, 2021 the Company owed Mr. Osser approximately $58,000 and $0, respectively, which is included accrued expense, related party in the condensed consolidated balance sheet.

Note 12 - Related Party Transactions

6 Months Ended

Jun. 30, 2022

NOTE 12 -- RELATED PARTY TRANSACTIONS

United Systems

Milestone Scientific has a manufacturing agreement with United Systems (whose controlling shareholder, Tom Cheng, is a significant stockholder of Milestone Scientific), the principal manufacturers of its handpieces, pursuant to which it manufactures products under specific purchase orders, but without minimum purchase commitments. Purchases from this manufacturer were approximately $436,000 and $1.7 million, respectively for three and six months ended June 30, 2022. Purchases from this manufacturer were approximately $493,000 and $878,000, respectively for three and six months ended June 30, 2021.

As of June 30, 2022 and December 31, 2021, Milestone Scientific owed this manufacturer approximately $720,000, and $548,000, respectively, which approximately $720,000 and $395,000 is included in accounts payable, related party, respectively, and $0 and approximately $153,000 is included in accrued expense, related party, respectively, on the unaudited condensed consolidated balance sheets.

Milestone China

See Note 6 of the notes to the unaudited condensed consolidated financial statements.

Other

In August 2016, K. Tucker Andersen, a significant stockholder of Milestone Scientific, entered into a three-year agreement with Milestone Scientific to provide financial and business strategic services. Expenses recognized on this agreement were $25,000 and $50,000 for three and six months ended June 30, 2022, and 2021.

The Company engaged Mr. Trombetta as a consultant for a period of twelve months (beginning October 1, 2020, and ending September 30, 2021), to provide international business dental information and business contacts to the Company and provide consulting services for new international business and dental segments. For the three and six months ended June 30, 2021, the Company expensed $15,000 and $30,000, respectively, for services rendered by Mr. Trombetta. Mr. Trombetta received shares of the Company’s common stock. This agreement was terminated September 30, 2021, and therefore, no expenses were incurred for services rendered by Mr. Trombetta for the three and six months ended June 30, 2022.

The Director of Clinical Affairs’ royalty fee was approximately $81,000 and $213,000 for three and six months ended June 30, 2022, respectively. The Director of Clinical Affairs’ royalty fee was approximately $111,000 and $248,000 for three and six months ended June 30, 2021, respectively. Additionally, Milestone Scientific expensed consulting fees to the Director of Clinical Affairs of $39,000 and $78,000 for three and six months ended June 30, 2022 and 2021, respectively. As of June 30, 2022 and December 31, 2021, Milestone Scientific owed the Director Clinical Affairs for royalties of approximately $81,000 and $123,000, respectively, which is included in accrued expense, related party, in the condensed consolidated balance sheet.

On March 2, 2021, Milestone Scientific entered into a Royalty Sharing Agreement with Leonard Osser, the Company’s then Interim Chief Executive Officer, pursuant to which Mr. Osser sold, transferred and assigned to the Company all of his rights in and to a certain patent application as to which he is a co-inventor with Dr. Hochman, and the Company agreed to pay to Mr. Osser, beginning May 9, 2027, half of the royalty (2.5%) on net sales that would otherwise be payable to Dr. Hochman and his wife under their Technology Sale Agreement with the Company, the Hochman's having agreed with the Company pursuant to an addendum to such Technology Sale Agreement dated February 25, 2021 to reduce from 5% to 2.5% the payments due to them on May 9, 2027 and thereafter, with respect to dental products.

Pursuant to a Succession Agreement dated April 6, 2021 between Mr. Osser and the Company: (i) the Employment Agreement dated as of July 10, 2017 between Mr. Osser and the Company, pursuant to which upon Mr. Osser stepping down as Interim Chief Executive Officer of the Company, the Company agreed to employ him as Managing Director, China Operations of the Company (the “China Operations Agreement”), and (ii) the Consulting Agreement dated as of July 10, 2017 (the “Consulting Agreement”) between the Company and U.S. Asian Consulting Group, LLC, a company of which Mr. Osser is a principal, the compensation under the China Operations Agreement was modified to reduce the overall compensation by $100,000 to $200,000, split equally between a cash amount and an amount in shares, and the compensation under the Consulting Agreement is increased by $100,000 to $200,000, equally split between a cash amount and an amount in shares, which shares were formerly payable under the China Operations Agreement. Compensation under the China Operations Agreement and the Consulting Agreement are payable for 9.5 years from May 19, 2021.

The Company recorded expense of $50,000 and $100,000 related to the Managing Director, China Operations for three and six months ended June 30, 2022, respectively. The Company recorded expense of $50,000 and $100,000 related to the US Asian Consulting Group, LLC for three and six months ended June 30, 2022, respectively. The Company recorded expense of $25,000 related to the Managing Director, China Operations for three and six months ended June 30, 2021, respectively. The Company recorded expense of $25,000 related to the US Asian Consulting Group, LLC for three and six months ended June 30, 2021, respectively. As of June 30, 2022 and December 31, 2021 the Company owed Mr. Osser approximately $58,000 and $0, respectively, which is included accrued expense, related party in the condensed consolidated balance sheet.